anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a water-soluble olive leaf extract health-care product, and belongs to the field of health-care products. The water-soluble olive leaf extract health-care product is prepared from 15-80 parts of olive leaf extracts, 5-40 parts of momordica charantia p-polypeptide and 0.1-1 part of chromium-rich beer yeast. The health-care product has the effects of regulating sensibility of a human body to insulin, promoting utilization of the human body to the insulin and regulating blood glucose. The invention further discloses a preparation method of the water-soluble olive leaf extract health-care product and a preparation method of the olive leaf extracts in the health-care product. The preparation method of the olive leaf extracts comprises the steps that olive leaves are taken, impurities are removed, crushing is conducted, and olive leaf crude powder is obtained; water and the olive leaf crude powder are extracted at least twice to obtain an extracting solution; the extracting solution is subjected to impurity removing in an alcohol precipitation mode, concentration is conducted, and concentrated thick paste is obtained; the concentrated thick paste is subjected to spray drying, and the olive leaf extracts are obtained. The preparation method of the olive leaf extracts is simple and environmentally friendly, the obtained olive leaf extracts are safe and reliable, and no harmful organic matter is brought in or left over.
Neuropathic corneal pain (NCP) is a new and ill-defined disease characterized by pain, discomfort, aching, burning sensation, irritation, dryness, and grittiness. However, the mechanism underlying NCP remain unclear. Here, we reported a novel rat model of primary NCP induced by long ciliary nerve (LCN) ligation. After sustained LCN ligation, the rats developed increased corneal mechanical and chemical sensitivity, spontaneous blinking, and photophobia, which were ameliorated by intraperitoneal injection of morphine or gabapentin. However, neither tear reduction nor corneal injury was observed in LCN-ligated rats. Furthermore, after LCN ligation, the rats displayed a significant reduction in corneal nerve density, as well as increased tortuosity and beading nerve ending. Long ciliary nerve ligation also notably elevated corneal responsiveness under resting or menthol-stimulated conditions. At a cellular level, we observed that LCN ligation increased calcitonin gene-related peptide (neuropeptide)-positive cells in the trigeminal ganglion (TG). At a molecular level, upregulated mRNA levels of ion channels Piezo2, TRPM8, and TRPV1, as well as inflammatory factors TNF-α, IL-1β, and IL-6, were also detected in the TG after LCN ligation. Meanwhile, consecutive oral gabapentin attenuated LCN ligation-induced corneal hyperalgesia and increased levels of ion channels and inflammation factors in TG. This study provides a reliable primary NCP model induced by LCN ligation in rats using a simple, minimally invasive surgery technique, which may help shed light on the underlying cellular and molecular bases of NCP and aid in developing a new treatment for the disease.
Bioactive substances are imbedded or mixed into functionalized matrices to form homogenous water-insoluble solid complexes with desirable field properties such as reduced leaching in soil, improved leaf retention (rainfastness), selective unloading to roots and convenient packaging and application. Bioactive substances that may be so complexed include pharmaceutical agents and pesticides including herbicides, insecticides, bacteriocides, rodenticides, nematicide and fungicides. The matrices comprise either a monomeric-, oligomeric- or (co)polymeric backbone which may be derivatized with chemical groups that exhibit ionic (amines, carboxyls), hydrophobic, and ligand-binding interactions to form the matrix of the formulation. The various matrices may be mixed with additives or modifiers, grafted, or fused to obtain optimal properties. The matrix/pesticide formulations may be applied as granules, as suspensions, emulsions in sprays, as foams, or as coats for seeds and fertilizers. Alternatively they may be melted and sprayed as concentrates. The formulations may be applied to foliage, soil, irrigation water, construction materials, seeding materials, grains, and buildings.
18-55 years old 100 patients with American Society of Anesthesiology (ASA) physical status I-II,who are planned to undergo for elective ureteroscopy will be participated in this study.In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.General anesthesia will be performed to all patients. After anesthesia induction with propofol 2mg/kg and rocuronium 0.6 mg/kg, patients will be ıntubated and mechanically ventilated. Maintenance of anesthesia will be achieved with 4-6 % desflurane in nitrous oxide/ oxygen (50%/50%) concentrations with the flow 5L/min. Tramadol 1 mg/kg and metoclopramid 1 ampul will be administered intravenously after intubation. Hemodynamic parameters( systolic blood pressure, diastolic blood pressure, heart rate and peripheral oxygen saturation), end tidal carbon dioxide values, the concentrations of inspired and exhaled desflurane will be recorded on the surgery start time and on the 5th, 15th,25th,35th,45th,60 th minutes of surgery. At the end of operation ,neuromuscular blockage will be reversed with neostigmine (0,05 mg/kg)and atropine sulphate 0,015 mg/kg i.v. Anesthesia time, surgery time, time of eye opening,time of transfer to the recovery room will be recorded in the operating room. In the recovery room pain score will be evaluated with Visual Analogue Scale. Modified Aldrete Recovery Score will be used for evaluating recovery.
A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
Changes in ovarian hormones across the menstrual cycle impact responses to cocaine in women. Studies have shown that cocaine's effects are dampened during the luteal phase of the menstrual cycle, when estrogen and progesterone concentrations are high, relative to the other phases of the cycle, when concentrations of these hormones are relatively low. The purpose of this study is to determine whether progesterone reduces subjective and physiological responses to cocaine in cocaine dependent individuals. In addition, this study will help to advance the possibility of hormonal progesterone and pharmacologically-related drugs as potential treatment components for cocaine abuse.

Participants will undergo two 4-day inpatient periods, totaling 8 days of treatment. For women, the inpatient periods will occur during two consecutive menstrual cycles; for men, these will occur during two consecutive months. On Day 1, participants will receive a first dose of either progesterone or placebo. On Day 2, participants will receive a second and third dose of study medication. Participants will also participate in an adaptation session, which will familiarize the participant with the smoking equipment that will be used the following day. On Day 3, participants will receive a fourth dose of medication 2 hours prior to a smoking lab session. Prior to beginning the smoking lab session, participants will be asked to rate their current cocaine craving, anxiety level, appetite, and premenstrual symptoms. Participants will then be given a sample of the cocaine dose for the given day. During the smoking lab session, participants will be asked additional cocaine craving questions at pre-determined intervals and will be given the option to trade in previously earned tokens for either money or a dose of cocaine. Following completion of the smoking lab session, participants will receive their fifth dose of medication.
Patients who are randomized to the intervention Self Care group will get advice and support on physical excercise, nutrition and symptom management to perform at home for 12 weeks. Once a week, patients will come to the hospital for follow-up and to exercise with a physiotherapist.
The invention discloses externally applied traditional Chinese medicine powder for treating lumbar disc herniation. The powder comprises the following five traditional Chinese medicines: obtuseleaf erycibe stem, Chinese clematis root, bark of girald daphne, draconis resin and borneol. The powder has few compatible medicines, is simple and convenient to operate and has quick curative effects. Externally mixed and applied, the powder stops pains quickly and has an instant effect of eliminating lumbar disc symptoms. Chinese clematis root is acrid in taste, is divergent, is damp, promotes diuresis, can stimulate the twelve meridians, can not only expel the exterior wind but also remove interior dampness, stimulates meridians and activates collaterals, can carry out guide and dispersing, is an important medicine for gout and is suitable for wind-cold-dampness arthralgia, inflexibility of joints, muscular paralysis, aches of muscles and bones and gastral cavity separated phlegm and retained fluid. The powder has the advantages that the medicine is absorbed via skins and achieves the aim of treating diseases and is not absorbed via gastrointestinal tracts, so the medicine does not have the side effects caused by administration, does not harm qi and blood of spleens and stomachs and can be used by all the persons as long as the skins are not allergic to the medicine during clinical application.
The remote control of the virtual glasses will be given to the hand that will not be interfered with, and the child will start, slow down or stop the application herself. Samsung Gear Oculus Guest 2 headset allows watching virtual reality applications.
The isolation of a sulfotransferase cDNA via an expression cloning strategy has revealed a sulfotransferase having 356 amino acids, with characteristics of type II transmembrane protein. When expressed as a soluble fusion protein, the enzyme is able to transfer sulfate from a sulfate donor to acceptor substrates containing terminal glucuronic acid. The isolated sulfotransferase can be utilized to prepare proteins having the HNK-1 carbohydrate epitope which is expressed on several neural adhesion glycoproteins and as a glycolipid, and is involved in cell interactions. The glucuronyltransferase and sulfotransferase are considered to be the key enzymes in the biosynthesis of this epitope, because the rest of the structure occurs often in glycoconjugates. Thus, a method is provided for the sulfonation of glucuronic acid, present on cell adhesion and neural cell adhesion molecules, by exposing the neural cell adhesion molecule to a recombinant sulfotranferase enzyme to generate the HNK-1 carbohydrate epitope thereon. Use of isolated or recombinant cDNA to generate the HNK-1 glycosylated recombinant L1-Fc fusion protein can thus facilitate various therapeutic methods where L1, or other members of its immunoglobulin superfamily, can be utilized, especially in the treatment of damaged or diseased neurons. The present invention includes methods of preparation of the sulfotransferase, neural adhesion molecules defining the HNK-1 carbohydrate epitope thereon, methods of promoting neural growth and/or remyelination and/or neuroprotection, and diagnostic utilities all utilizing the molecules and materials disclosed herein.
The invention concerns heterocyclic substances and, in particular, receptions substituted 1, 3, 4, 9 - tetrahydropyrano/3,4-indole-1-acetic acids or pharmaceutically acceptable salts thereof of the general formula:   Where R1 - C1-C4-alkyl; R2=R3-H or R2+R3 =-CH-CH-CH-CH-(is a part of a benzene ring), R4 and R5 - H, С1, C1-C6-alkyl possessing anti-inflammatory and anesthetizing properties, that can be used in medicine. The purpose of the invention is creation of new, more active materials of the specified class. Synthesis is conducted by condensation of corresponding isatin with ester enolate of the formula CHR3=CR1-CH2-CH2-C (O)-O-CH3 at presence of lithium diisopropanolamine at temperature from-78°С up to room in the nedium of organic solvent. The obtained compound without isolation is reduced by means of lithium aluminum hydride with the subsequent processing by a methylic ether 3-methoxy-2 C1-C4-alkene acids and hydrolysis of the received ether. The main product in the form of the basis or salts possesses higher activity without display of by-effects.          3 tables
The present invention discloses one kind of over-the-counter medicine, named as Yangrongtongbining, for treating tetanic rachitis and other diseases. It is prepared with 28 kinds of Chinese medicinal materials, including ginseng, wolfberry fruit, angelica, etc. and is prepared into capsule, tablet or bolus. It has the functions of invigorating vital energy and blood, strengthening body's resistance, relaxing muscles and joints, stopping pain, etc. and may be used to cure tetanic rachitis radically. It has also high curative effect on rheumarthritis, rheumatoid arthritis, pain waist and legs, etc.
PET with the tracer \[18F\]DPA-714 and second PET with the tracer \[11C\]-PE2I. \[18F\]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. \[11C\]-PE2I allow measures dopaminergic neuronal loss.
Background: The use of Aromatase Inhibitors (AIs) among breast cancer (BC) patients with hormone receptor-positive disease reduces recurrence by 41% and mortality by 31%. Despite the efficacy of AIs, one-quarter of BC survivors fail to take their AIs as prescribed during the first year with another one-fifth discontinuing later in treatment. There are a variety of reasons for non-adherence, including low motivation, poor patient-provider communication, low self-efficacy, low perceived risk, and the experience of side effects. One promising intervention for improving treatment adherence is motivational interviewing (MI), a broad set of patient-centered techniques designed to enhance motivation for behaviour change. Objectives: To conduct a parallel-group, double-blind, randomized controlled trial (RCT) to evaluate the efficacy of MI at improving 12-month adherence to AIs relative to attention control (AC). The primary outcome is medication adherence measured using pharmacy records and calculated by medication possession ratio (MPR). Secondary outcomes include self-reported adherence, motivation and self-efficacy. Methods: A community sample of BC survivors newly prescribed AIs will be recruited from a local cancer centre pharmacy for a 6-month medication adherence observation period. The investigators chose to recruit new AI users because a significant number (i.e., 20-35%) are expected to discontinue medication within 12-months. MPR will be calculated following the observation period and patients meeting inclusion criteria and deemed non-adherent (MPR \< 80%) will be enrolled in the trial, randomly assigned to MI or AC, and scheduled for a baseline appointment. Recruitment will continue until 128 (64 per group) non-adherent BC survivors are identified. Four MI or AC sessions will be delivered at 3-month intervals (0-,3-,6-,9-months), each lasting 30-45 minutes. A final assessment will occur at 12-months. Baseline and final assessments will be conducted by an assistant who is not affiliated with the trial. Given that the long-term adherence to AIs is poor, a lack of adherence leads to clinically meaningful increases in BC recurrence, morbidity and mortality, and there has been only one published intervention study related to AIs to date, our trial represents a top priority in the prevention and treatment of BC.
After hospital discharge, many people experience difficulty in managing their medication regimens. This can be due to medication dosing changes, challenges in adjusting new medications with those that were taken previously, inadequate discharge instructions from hospital personnel, and inadequate follow-up. Difficulty with medication management can lead to medication errors that result in harmful side effects, poor disease control, hospital readmission, or even death. People with low health literacy often have greater difficulty with understanding and managing their medication regimens and as a result they experience more medication use errors. Although research shows that many medication errors could be prevented or lessened through improved doctor communication and patient-centered treatment programs, little research has been done on the effectiveness of such programs among low-literacy patients or of such programs during key transition times like hospital discharge. Getting pharmacists involved with patient care before hospital discharge may prevent unnecessary and dangerous medication errors from occurring once patients leave the hospital. Because of the severity of heart conditions and the likelihood of serious adverse effects from non-compliance with heart medications, this study will evaluate people admitted to the hospital for acute coronary syndromes or heart failure. The purpose of this study is to evaluate the effectiveness of a health literacy-focused, pharmacist-delivered program at reducing medication errors in heart patients during the first month after hospital discharge.

This study will enroll people admitted to the hospital who have acute coronary syndromes or heart failure. Participants will be randomly assigned to either the pharmacist-delivered program or usual care. Participants assigned to the intervention group will receive a pharmacist-assisted medication review while in the hospital, counseling from a pharmacist at the time of hospital discharge, a low-literacy education tool that details the discharge medications, a follow-up phone call 1 to 4 days after discharge, and additional phone calls as needed. Participants receiving usual care will receive a doctor-assisted medication review and nurse-provided guidance on medication usage at the time of hospital discharge. Approximately 30 days after hospital discharge, study researchers will call all participants to collect information on serious medication errors, health care utilization, and disease-specific quality of life.
Standardized grass pollen extract is indicated for use in the diagnosis of grass allergy in patients with a history of allergic symptoms that occur during grass pollination. Skin tests with standardized grass pollen extract should be done first by the puncture method using 10,000 BAU/mL extract. If these tests are negative, they may be repeated by the puncture method with 100,000 BAU/mL extract, or by the intradermal method using an appropriate dilution (see DOSAGE AND ADMINISTRATION). The extract also is indicated for use in the treatment of allergic symptoms by immunotherapy in patients with a history of grass pollen allergy and established sensitivity to grass pollen extract by skin testing. The availability of 10,000 and 100,000 BAU/mL extracts facilitates dose selection for safe switching to standardized grass pollen extracts. Previously untreated patients should be initially treated with appropriately diluted 10,000 BAU/mL. If tolerated, higher doses may be indicated. The use of grass pollen extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook 13. 

Allermed's standardized grass pollen extracts labeled in BAU/mL are not interchangeable with alumprecipitated grass pollen extracts, grass pollen extracts labeled in AU/mL or non-standardized grass pollen extracts.
The pharmacokinetics of neostigmine methylsulfate in patients with hepatic impairment have not been studied. Neostigmine methylsulfate is metabolized by microsomal enzymes in the liver. No adjustments to the dosing of BLOXIVERZ appear to be warranted in patients with hepatic insufficiency. However, patients should be carefully monitored if hepatically cleared neuromuscular blocking agents were used during their surgical procedure as their duration of action may be prolonged by hepatic insufficiency whereas BLOXIVERZ, which undergoes renal elimination, will not likely be affected. This could result in the effects of the neuromuscular blocking agent outlasting those of BLOXIVERZ. This same situation may arise if the neuromuscular blocking agent has active metabolites. In this regard, the interval for re-dosing the neuromuscular blocking agent during the surgical procedure may be useful in determining whether, and to what extent, post-operative monitoring needs to be extended.
BACKGROUND: Reconstruction of extensive defects remains a challenge. The authors report their experience with extensive defect reconstruction using multiple perforator propeller flaps and provide a systematic review of the literature on this approach.
METHODS: This retrospective study included patients who underwent defect reconstruction with multiple perforator propeller flaps from 2014 to 2021. A systematic review was conducted by retrieving studies on reconstructive strategy from PubMed, Web of Science, Embase, and Scopus published before December 1, 2022.
RESULTS: Thirty patients underwent defect reconstruction using 65 perforator propeller flaps. The posterior trunk (66.7%) was the most common site of defects. Complete flap survival was achieved in 61 flaps (93.8%). Partial necrosis of 4 flaps in 3 patients and venous congestion of 1 flap resulted in an overall complication rate of 13.3%. One flap experienced distal tip necrosis in 21 patients undergoing posterior trunk or perineal defect reconstruction, leading to an overall complication rate of 4.7%. Other complications were observed during the reconstruction of defects in the lower extremities (1 of 5 patients) and anterior trunk (2 of 4 patients). In the systematic review, 11 articles involving 74 patients were identified. Commonly reported locations of the defects were the perineum (55.4%) and posterior trunk (33.8%). Flap-related complications included venous congestion; no flaps were lost.
CONCLUSION: This study on the use of multiple perforator propeller flaps in a jigsaw puzzle approach demonstrated that the method can be used effectively for extensive posterior trunk and perineal defect reconstruction.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.